TIL Therapy for Advanced Melanoma Requires Nursing, Pharmacy Collaboration
Source: Oncology Nursing News, March 2024
An oncology nurse and pharmacist discuss the multidisciplinary approach to administering TIL therapy in patients with advanced melanoma.
The administration of lifileucel (Amtagvi) for the treatment of patients with unresectable or metastatic melanoma requires close collaboration between oncology nurses and pharmacists to address patient questions and manage potential side effects.
In February 2024, the first individualized T-cell therapy for a solid tumor—lifileucel—was approved by the FDA for the treatment of adult patients with unresectable or metastatic melanoma. As oncology nurses and other members of the care team learn more about the administration of this therapy, a multidisciplinary approach to treatment becomes critical.